The IUPAC name for abrocitinib is N-(3-cyano-4-(2-(methylsulfonyl)phenyl)phenyl)-2-(5-hydroxy-1,1-dioxo-1,2-thiazol-3-yl)acetamide [1]. PubChem provides this identification as part of its chemical database, which is a repository of information on chemical substances [2].
What is Abrocitinib Used For?
Abrocitinib is a medication used to treat adults with moderate-to-severe atopic dermatitis that is associated with characteristic lesions and symptoms for systemic therapy [3]. It is an oral Janus kinase 1 (JAK1) selective inhibitor [3].
How Does Abrocitinib Work?
Abrocitinib selectively inhibits JAK1. By inhibiting JAK1, it interferes with signaling pathways that contribute to inflammation and the immune response involved in atopic dermatitis [3]. This action helps to reduce the itching and skin lesions associated with the condition.
When Does Abrocitinib's Patent Expire?
Information on specific patent expiration dates for abrocitinib may be available through specialized patent databases like DrugPatentWatch.com. These resources track patent filings and expiration timelines for pharmaceutical products [4].
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer [3].
What are the Side Effects of Abrocitinib?
Common side effects of abrocitinib include acne, nausea, cough, headache, and an increase in blood creatine phosphokinase [3]. More serious side effects can include infections, changes in certain blood counts (such as anemia or low white blood cell count), and blood clots [3]. Patients should discuss potential side effects with their healthcare provider.
How Does Abrocitinib Compare to Other Atopic Dermatitis Treatments?
Abrocitinib belongs to a class of drugs known as JAK inhibitors, which offer a targeted approach to managing inflammation in atopic dermatitis. It is an oral medication, distinguishing it from topical treatments. Clinical studies have demonstrated its efficacy in reducing itch and skin severity compared to placebo [3]. Comparisons with other JAK inhibitors or biologic therapies for atopic dermatitis would involve evaluating differences in efficacy, safety profiles, and administration routes [3].
Are There Any Safety Concerns with Abrocitinib?
Like other JAK inhibitors, abrocitinib carries a boxed warning in the U.S. regarding the increased risk of serious infections, mortality, major cardiovascular events, and thrombosis [3]. Patients with pre-existing conditions or those taking certain other medications may be at higher risk [3].
Can Patients Take Abrocitinib with Other Medications?
Abrocitinib can interact with other medications. For instance, it may increase the risk of certain infections when used with other immunosuppressants [3]. Patients should provide their healthcare provider with a complete list of all medications they are taking before starting abrocitinib [3].
---
1. PubChem. (n.d.). Abrocitinib. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Abrocitinib
2. PubChem. (n.d.). About PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/about
3. Pfizer Inc. (2023). CIBINQO® (abrocitinib) Prescribing Information. https://www.pfizer.com/sites/default/files/cibinqo_pi.pdf
4. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/